The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
19 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,952,048 in first-year total cost, median $534,125.
Most frequent study sections
- Drug Discovery for the Nervous System Study Section[DDNS]17
- Drug Discovery for the Nervous System Study Section[DDNS-R]1
- Special Emphasis Panel[ZRG1 MDCN-G (05)]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
- VANDERBILT UNIVERSITY2
- ALBANY COLLEGE OF PHARMACY1
- BRIGHAM AND WOMEN'S HOSPITAL1
- J. DAVID GLADSTONE INSTITUTES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Identification and Development of Tau-Lowering Small-Molecule Drugs1R56AG060631-01A1 | MUCKE, LENNART | J. DAVID GLADSTONE INSTITUTES, CA | $1,703,867 | DDNS |
| 2019 | Discovery of mGlu receptor PAMs for treatment of schizophrenia1R01MH119673-01 | CONN, P JEFFREY | VANDERBILT UNIVERSITY, TN | $752,218 | DDNS |
| 2019 | Novel Protein Aggregation Inhibitors and Upper Motor Neuron Stabilizers for ALS and other Neurodegenerative Diseases1R01AG061708-01A1 | OZDINLER, PEMBE HANDESILVERMAN, RICHARD B | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $671,753 | DDNS |
| 2019 | High Throughput screen to identify "first of their kind" activators of ADCY101R01AG061290-01 | BUCK, JOCHENLEVIN, LONNY R | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $566,037 | DDNS |
| 2019 | Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain1R01DA048879-01 | CIOFFI, CHRISTOPHER L.VANDENBERG, ROBERT JOHN | ALBANY COLLEGE OF PHARMACY, NY | $534,125 | DDNS |
| 2019 | Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease1R01AG061151-01 | MOBLEY, WILLIAM C | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $463,515 | DDNS |
| 2019 | Hyperphosphorylated tau aggregation-based Alzheimer’s disease early drug discovery1R01AG062435-01 | KUO, MIN-HAO | MICHIGAN STATE UNIVERSITY, MI | $431,676 | DDNS |
| 2019 | Structural Determinants of Allosteric Modulation of Brain GPCRs1R01DA046138-01A1 | MEILER, JENS | VANDERBILT UNIVERSITY, TN | $394,756 | DDNS |
| 2019 | A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease1R01AG062840-01A1 | SUMBRIA, RACHITA | KECK GRADUATE INST OF APPLIED LIFE SCIS, CA | $390,183 | DDNS |
| 2019 | Antisense Oligonucleotides for Targeting Nonsense-mediated mRNA Decay in Frontotemporal Dementia1R01AG064069-01 | NGUYEN, ANDREW D. | SAINT LOUIS UNIVERSITY, MO | $375,403 | DDNS |
| 2018 | AD Immunotherapy with a Novel CDC-Mutant Anti-Pyroglutamate-3 Abeta Antibody to Avoid Vascular Side Effects1RF1AG058657-01 | LEMERE, CYNTHIA A | BRIGHAM AND WOMEN'S HOSPITAL, MA | $2,151,385 | DDNS |
| 2018 | Impact of Physical Activity on Striatal Reinnervation in a Nonhuman Primate Model of Parkinson's Disease1R56AG059284-01 | DAADI, MARCEL | TEXAS BIOMEDICAL RESEARCH INSTITUTE, TX | $710,357 | DDNS |
| 2018 | Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists1R01AG057658-01 | COLE, GREGORY MTALBOT, KONRAD | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $682,885 | DDNS |
| 2018 | Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease1R01AG055523-01A1 | MOBLEY, WILLIAM C | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $499,198 | DDNS |
| 2018 | Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease1R01AG059799-01 | ROJAS, CAMILOSLUSHER, BARBARA STAUCHTSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $492,421 | DDNS |
| 2018 | Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease1R01AG057598-01 | SCHIEFER, ISAAC T | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS, OH | $383,750 | DDNS |
| 2017 | Pain drugs based on nicotinic receptor subtype antagonists1R01DA041454-01A1 | GEE, KELVIN W. | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $790,424 | DDNS |
| 2017 | Estrogen therapy and APOE4 risk in Alzheimer's tested in female EFAD mice1R01AG057008-01 | LADU, MARY JOTHATCHER, GREGORY R. J | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $578,095 | ZRG1 |
| 2017 | Effects of glycomacropeptide on memory and Alzheimer-related neuropathology1R01AG054562-01 | MCDONALD, MICHAEL P | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $380,000 | DDNS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.